

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)



(10) International Publication Number
WO 2023/073661 A2

(51) International Patent Classification:
C12N 15/113 (2010.01) A61K 31/7105 (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/IB2022/060478

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
31 October 2022 (31.10.2022)

(25) Filing Language: English

(26) Publication Language: English

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(30) Priority Data:
63/274,405 01 November 2021 (01.11.2021) US

(71) Applicant: **IONIS PHARMACEUTICALS, INC.**
[US/US]; 2855 Gazelle Court, Carlsbad, California 92010 (US).

(72) Inventors: **BUI, Huynh-Hoa**; Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, California 92010 (US). **FREIER, Susan M.**; Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, California 92010 (US). **LEE, Richard**; 1405 Willow Creek Dr., Vista, California 92084 (US).

(74) Agent: **BRASLOW, Kimberly**; AstraZeneca Intellectual Property, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: COMPOUNDS AND METHODS FOR REDUCING PSD3 EXPRESSION

(57) Abstract: Provided are compositions of matter including oligomeric agents, modified oligonucleotides, oligomeric compounds, and pharmaceutical compositions, and methods of use thereof, for reducing the amount or activity of PSD3 RNA in a cell or animal, and in certain instances reducing the amount of PSD3 protein in a cell or animal. Such compositions are useful to treat liver disease, fatty liver disease (FLD), nonalcoholic fatty liver disease (NAFLD), hepatic steatosis, non-alcoholic steatohepatitis (NASH), liver cirrhosis, hepatocellular carcinoma, alcoholic liver disease, alcoholic steatohepatitis (ASH), HCV hepatitis, chronic hepatitis, hereditary hemochromatosis, or primary sclerosing cholangitis.



WO 2023/073661 A2